Posted Sep 27, 2022, 6:06 PMUpdated on Sep 27, 2022 at 6:07 PM
Inventiva, a biotech with a hundred employees whose head office is located in Daix, near Dijon (Côte-d’Or), has just signed a major agreement with the Chinese Sino Biopharm to develop its treatment against non-alcoholic steatohepatitis , commonly referred to as “soda sickness” or “fatty liver disease”.
This agreement will allow the biotech to receive up to 290 million dollars (293.6 million euros). It provides for clinical milestone payments, the first of which is $12 million.
Non-alcoholic steatohepatitis is a serious pathology, referred to by the acronym NASH in English. It consists of an overload of fat in the liver, accompanied by inflammation and cell damage. The disease is particularly detected in the United States and China and would affect more than 200,000 people in France at a severe stage, according to Inserm. The treatment is being evaluated in a Phase III clinical study (the last), Inventiva said. This phase, which concerns human trials, should be completed by the end of 2025.
A market estimated between 20 to 30 billion dollars
Sino Biopharm, a major Chinese pharmaceutical group, will oversee the development and commercialization in China of lanifibranor, a molecule to which the American Food and Drug Administration (FDA) has granted the status of “Breakthrough Therapy” (“particularly innovative treatment”) to the following the publication of positive results from the first clinical studies.
This treatment, which has already received very significant funding of 50 million euros from the European Investment Bank, is targeting a market estimated at between 20 and 30 billion dollars, according to independent experts.
(With AFP)
What benchmarks in a constantly changing world?
Political uncertainties, scientific innovations, war in Ukraine, energy and ecological transition… How to understand these changes? How to position yourself? Every day, the 200 journalists from the “Echos” editorial staff help you decipher economic, political and international news through surveys, analyses, press reviews, chronicles and editorials. Our subscribers know that they can rely on these resources to better navigate our complex environment and make the best strategic decisions.
